The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

Regeneron Pharmaceuticals agreed to purchase 23andMe for $256 million in a bankruptcy court auction, the company said Monday. The move allows 23andMe to continue to provide DNA testing services ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy-protection ...

She regularly appears on CBS News 24/7 to discuss her reporting. Regeneron has agreed to buy 23andMe, the once buzzy genetic testing company, out of bankruptcy for $256 million under a court ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

Matthew Herper covers medical innovation — both its promise and its perils. Regeneron Pharmaceuticals said Monday it had entered into an agreement to buy the consumer genetics firm 23andMe out ...

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...

HWK-016 is the only known ADC that targets the membrane-bound portion of MUC16, a glycoprotein with ... So considering that Regeneron is developing a Mucin 16 targeted bispec antibody for ovarian ...

Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023; Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding Ronapreve TM( ...

Report additional data for ubamatamab (MUC16 and CD3 bispecific antibody) in ovarian cancer - Report additional data from solid tumor costimulatory bispecific antibody programs Hematology ...